Table 2. Patients characteristics.
|
Type of adjuvant chemotherapy |
||||||||
|---|---|---|---|---|---|---|---|---|
|
All patients |
None |
CMF |
Anthra-based |
|||||
| Characteristic No. of patients |
291 |
101 |
109 |
81 |
||||
| No | (%) | No | (%) | No | (%) | No | (%) | |
| Age (years) | ||||||||
| <50 | 103 | (35.4) | 24 | (23.8) | 48 | (44.0) | 31 | (38.3) |
| 51–60 | 104 | (35.7) | 34 | (33.7) | 42 | (38.5) | 28 | (34.6) |
| 61–73 | 84 | (28.9) | 43 | (42.6) | 19 | (17.4) | 22 | (27.2) |
| Performance status | ||||||||
| 0 | 255 | (87.6) | 85 | (84.2) | 97 | (89.0) | 73 | (90.1) |
| 1 | 31 | (10.7) | 14 | (13.9) | 11 | (10.1) | 6 | (7.4) |
| >2 | 5 | (1.7) | 2 | (1.9) | 1 | (0.9) | 2 | (2.5) |
| Oestrogen receptor status | ||||||||
| Positive | 150 | (51.5) | 52 | (51.5) | 57 | (52.3) | 41 | (50.6) |
| Negative | 69 | (23.7) | 16 | (15.8) | 32 | (29.4) | 21 | (25.9) |
| Unknown | 72 | (24.8) | 33 | (32.7) | 20 | (18.3) | 19 | (23.5) |
| Axillary nodes | ||||||||
| Positive | 136 | (46.7) | 20 | (19.8) | 72 | (66.1) | 44 | (54.3) |
| Negative | 75 | (25.8) | 53 | (52.5) | 8 | (7.3) | 14 | (17.3) |
| Unknown | 80 | (27.5) | 28 | (27.7) | 29 | (26.6) | 23 | (28.4) |
| DFI | ||||||||
| 1 year | 17 | (5.8) | 14 | (13.9) | 1 | (0.9) | 2 | (2.5) |
| 1 years to 3 years | 112 | (38.5) | 19 | (18.8) | 52 | (47.7) | 41 | (50.6) |
| 3 years to 5 years | 62 | (21.3) | 21 | (20.8) | 24 | (22.0) | 17 | (21.0) |
| >5 years | 100 | (34.4) | 47 | (46.5) | 32 | (29.4) | 21 | (25.9) |
| Dominant metastatic site | ||||||||
| Viscera | 206 | (70.8) | 65 | (64.4) | 80 | (73.4) | 61 | (75.3) |
| Soft tissues | 51 | (17.5) | 18 | (17.8) | 18 | (16.5) | 15 | (18.5) |
| Bone | 34 | (11.7) | 18 | (17.8) | 11 | (10.1) | 5 | (6.2) |
| HDCT | 32 | (10.9) | 10 | (9.9) | 12 | (11.0) | 10 | (12.3) |
| HT | 44 | (15.1) | 16 | (15.8) | 15 | (13.7) | 13 | (16.0) |
| Median cumulative epi, range (mg sqm−2) | 540 | 540 | 900 | |||||
| (90–720) | (90–720) | (450–1080) | ||||||
CMF=Cyclophosplamide plus methotrexate plus 5-fluorouracil; DFI=disease-free interval.
HDCT=High Dose Chemotherapy
HT=Hormonal Therapy for Metastatic Disease